|
Medicare’s drug plan: huge price disparities for common cancer drugs
1 Center for Practical Health Reform, Atlantic Beach, FL, and
2 Coalition to Advance Prescription Drug Education (CARxE), San Francisco, CA
The editors of Community Oncology chose seven oral cancer drugs and asked the authors to analyze differences in pricing among the drugs within three communities, each market a different size. The drugs are anastrozole (Arimidex), exemestane (Aromasin), imatinib (Gleevec), sunitinib (Sutent), erlotinib (Tarceva), temozolomide (Temodar), and thalidomide (Thalomid). The markets are Chicago, Illinois; Portland, Oregon; and Virginia Beach, Virginia. The results of this small study offer a stark illustration of the difficult nature of Medicare’s Part D program.
| Commun Oncol 2006;3:753–755 | full text |  68 kb |